Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
8 hedge funds and large institutions have $1.04M invested in Sonnet BioTherapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
100% more funds holding
Funds holding: 4 → 8 (+4)
13% more capital invested
Capital invested by funds: $921K → $1.04M (+$117K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$260K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$72.1K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$57.7K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$36K |
| 5 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$16K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $619K | – | – | – |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $228K | +$260K | +36 | New |
|
|
SFI
3
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| $63K | +$72.1K | +10 | New |
|
|
ASN
4
Advisory Services Network
Atlanta,
Georgia
| $48K | +$57.7K | +8 | New |
|
|
SSA
5
Schonfeld Strategic Advisors
New York
| $31K | +$36K | +5 | New |
|
|
IWM
6
IHT Wealth Management
Chicago,
Illinois
| $26K | +$28.8K | +4 | New |
|
|
RFA
7
Reilly Financial Advisors
La Mesa,
California
| $14K | +$7.21K | +1 | +100% |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $7K | -$7.21K | -1 | -50% |
|
|
FWM
9
Focused Wealth Management
Newburgh,
New York
| $1K | – | – | – |
|
|
JCM
10
Jacobi Capital Management
Pittston,
Pennsylvania
| $1K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$16K | -2 | Closed |
|
SONN Hedge Fund Activity: Q3 2020 in Review
8 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2020, worth a combined $1.04M — up 13% from $921K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SONN positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $260K. The largest seller was UBS Group, exiting entirely with an estimated $16K sold.
- 8 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2020, up from 4 in Q2 2020.
- Funds reported $1.04M of Sonnet BioTherapeutics stock for Q3 2020, up 13% quarter-over-quarter.
- 5 funds opened new Sonnet BioTherapeutics positions in Q3 2020 and 1 closed out, a net change of +4 holders.
- The largest Sonnet BioTherapeutics buyer in Q3 2020 was Vanguard Group, an estimated $260K added.
- The largest Sonnet BioTherapeutics seller in Q3 2020 was UBS Group, an estimated $16K sold.
Based on aggregated 13F filings for Q3 2020.